The presumed central nervous system effects of rocuronium in a neonate and its reversal with sugammadex
Authors:
- 12 October 2015
- journal article
- case report
- Published by Wiley in Pediatric Anesthesia
- Vol. 26 (1) , 109-111
Abstract
Summary: We describe a 2‐day‐old male infant who received rocuronium as part of general anesthesia for a tracheal esophageal fistula repair. Postoperatively, he had prolonged central and peripheral neuromuscular blockade despite cessation of the rocuronium infusion several hours previously. This case discusses the presumed central nervous system effects of rocuronium in a neonate and its effective reversal with sugammadex.Keywords
This publication has 17 references indexed in Scilit:
- Sugammadex, a Neuromuscular Blockade Reversal Agent, Causes Neuronal Apoptosis in Primary CulturesInternational Journal of Medical Sciences, 2013
- Drug Transport across the Blood–Brain BarrierJournal of Cerebral Blood Flow & Metabolism, 2012
- Pupillary Response to Light Is Preserved in the Majority of Patients Undergoing Rapid Sequence IntubationAnnals of Emergency Medicine, 2011
- Reversal of Rocuronium-induced Neuromuscular Blockade with Sugammadex in Pediatric and Adult Surgical PatientsAnesthesiology, 2009
- Sugammadex: Another Milestone in Clinical Neuromuscular PharmacologyAnesthesia & Analgesia, 2007
- Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anaesthetized Rhesus monkeyBritish Journal of Anaesthesia, 2006
- Rocuronium: the newest aminosteroid neuromuscular blocking drugBritish Journal of Anaesthesia, 1996
- Activation of Brain Acetylcholine Receptors by Neuromuscular Blocking DrugsAnesthesiology, 1994
- Blood-brain barrier permeability in “healthy” infected and stressed neonatesThe Journal of Pediatrics, 1992
- Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphomaEuropean Journal of Cancer and Clinical Oncology, 1991